News
BTTAY
24.23
NaN%
--
Weekly Report: what happened at BTTAY last week (0908-0912)?
Weekly Report · 09/15/2025 09:33
Weekly Report: what happened at BTTAY last week (0901-0905)?
Weekly Report · 09/08/2025 09:35
Weekly Report: what happened at BTTAY last week (0825-0829)?
Weekly Report · 09/01/2025 09:33
Weekly Report: what happened at BTTAY last week (0818-0822)?
Weekly Report · 08/25/2025 09:35
Weekly Report: what happened at BTTAY last week (0811-0815)?
Weekly Report · 08/18/2025 09:33
Weekly Report: what happened at BTTAY last week (0804-0808)?
Weekly Report · 08/11/2025 09:35
Weekly Report: what happened at BTTAY last week (0728-0801)?
Weekly Report · 08/04/2025 09:37
Weekly Report: what happened at BTTAY last week (0721-0725)?
Weekly Report · 07/28/2025 09:37
Weekly Report: what happened at BTTAY last week (0714-0718)?
Weekly Report · 07/21/2025 09:34
Weekly Report: what happened at BTTAY last week (0707-0711)?
Weekly Report · 07/14/2025 09:36
Weekly Report: what happened at BTTAY last week (0630-0704)?
Weekly Report · 07/07/2025 09:34
Weekly Report: what happened at BTTAY last week (0623-0627)?
Weekly Report · 06/30/2025 09:36
Weekly Report: what happened at BTTAY last week (0616-0620)?
Weekly Report · 06/23/2025 09:34
Weekly Report: what happened at BTTAY last week (0609-0613)?
Weekly Report · 06/16/2025 09:36
More
Webull provides a variety of real-time BTTAY stock news. You can receive the latest news about BIOTEST GMBH AND CO. KGAA through multiple platforms. This information may help you make smarter investment decisions.
About BTTAY
Biotest Gmbh and Co. KgaA, formerly known as Biotest AG, is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.